TABLE 1.

Summary of the predicted steady-state C_max and AUC geometric mean ratios for standard-dose ETI in the presence and absence of NTM treatments

NTM treatment	ETI	Predicted GMR (90% CI) of ETI PK parameter in the presence and absence of NTM treatmenta
		C max	AUC
Rifabutin, 300 mg daily	Elexacaftor, 200 mg daily	0.74 (0.73, 0.76)	0.67 (0.66, 0.69)
	Tezacaftor, 100 mg daily	0.74 (0.72, 0.76)	0.60 (0.58, 0.62)
	Ivacaftor, 150 mg q12h	0.37 (0.34, 0.39)	0.31 (0.29, 0.34)
Clofazimine, 100 mg daily	Elexacaftor, 200 mg daily	1.60 (1.57, 1.64)	1.75 (1.71, 1.80)
	Tezacaftor, 100 mg daily	1.51 (1.48, 1.55)	1.87 (1.82, 1.91)
	Ivacaftor, 150 mg q12h	2.48 (2.39, 2.57)	2.98 (2.88, 3.08)
Clarithromycin, 500 mg q12h	Elexacaftor, 200 mg daily	2.14 (2.02, 2.27)	2.43 (2.27, 2.59)
	Tezacaftor, 100 mg daily	2.11 (1.99, 2.24)	2.92 (2.73, 3.12)
	Ivacaftor, 150 mg q12h	7.28 (6.31, 8.41)	9.64 (8.33, 11.16)

^aGMR, geometric mean ratio.